Abstract | BACKGROUND: METHODS: We performed a systematic overview of individual patient data from all completed randomized controlled trials of pexelizumab to evaluate the effect on all-cause mortality at 30 and 180 days after treatment. We used a random effects model and included all 5916 patients randomized in 4 clinical trials. Patients received placebo, pexelizumab bolus only or pexelizumab bolus followed by a 24-hour infusion. RESULTS: A significant reduction in mortality at 30 days was observed in patients treated with bolus plus infusion (n = 2476) compared with placebo (n = 2492) (2.9% vs 4.2%; relative risk [RR], 0.70; 95% confidence interval [CI], 0.52-0.95; P = .02), with no interaction according to disease state of CABG or acute MI (P for interaction .33). A trend toward a reduction in mortality was observed in patients who received bolus plus infusion or bolus only (n = 3429) compared with placebo (n = 2476) (3.5% vs 4.2%; RR, 0.85; 95% CI, 0.66-1.0975; P = .215), but not in patients who received bolus only (n = 937) compared with placebo (n = 937) (5.2% vs 5.4%; RR, 0.96; 95% CI, 0.66-1.41; P = .918). The mortality benefit with bolus plus infusion compared with placebo persisted through 180 days (P = .05). CONCLUSIONS:
Pexelizumab reduced 30-day mortality in this systematic evaluation. Bolus plus infusion dose is being studied in ongoing trials in acute MI and CABG populations.
|
Authors | Kenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, Christopher B Granger, Edward D Verrier, Thomas G Filloon, Thomas G Todaro, Peter X Adams, Jerrold H Levy, Vic Hasselblad, Paul W Armstrong |
Journal | American heart journal
(Am Heart J)
Vol. 152
Issue 2
Pg. 291-6
(Aug 2006)
ISSN: 1097-6744 [Electronic] United States |
PMID | 16875911
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Complement C5
- Immunologic Factors
- Single-Chain Antibodies
- pexelizumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Complement C5
(antagonists & inhibitors)
- Coronary Artery Bypass
(mortality)
- Female
- Humans
- Immunologic Factors
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, mortality)
- Randomized Controlled Trials as Topic
- Reperfusion Injury
(prevention & control)
- Single-Chain Antibodies
|